Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha]
Sarepta Therapeutics, Inc. (SRPT)
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investorrelations.sarepta.com/events-and-presentations
Company Research
Source: Seeking Alpha
Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q1 2019 Results - Earnings Call Transcript Sarepta Therapeutics, Inc. (NASDAQ: SRPT Company Participants Ian Estepan - Senior Vice President, Chief of Staff and Corporate Affairs Douglas Ingram - President and Chief Executive Officer Sandy Mahatme - Executive Vice President, Chief Financial Officer and Chief Business Officer Bo Cumbo - Executive Vice President and Chief Commercial Officer Louise Rodino-Klapac - Senior Vice President, Gene Therapy Gilmore O'Neill - Executive Vice President, R&D and Chief Medical Officer Michael Triplett - President and Chief Executive Officer, Myonexus Therapeutics, Inc. Conference Call Participants Alethia Young - Cantor Fitzgerald & Co. Ritu Baral - Cowen & Co, LLC Brian Abrahams - RBC Capital Markets Tazeen Ahmad - Bank of America Merrill Lynch Maxwell Skor - Morgan Stanley Debjit Chattopadhyay - H.C. Wainwright & Co., LLC Christopher Marai - Nomura Holdings, Inc. Mark Connolly - Credit Suisse
Show less
Read more
Impact Snapshot
Event Time:
SRPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRPT alerts
High impacting Sarepta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRPT
News
- Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its price target lowered by analysts at JPMorgan Chase & Co. from $177.00 to $175.00. They now have an "overweight" rating on the stock.MarketBeat
- Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health [Yahoo! Finance]Yahoo! Finance
- Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global HealthBusiness Wire
- Sarepta Elevidys accelerated approval criticized by ICER exec [Seeking Alpha]Seeking Alpha
- Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y [Yahoo! Finance]Yahoo! Finance
SRPT
Earnings
- 5/1/24 - Beat
SRPT
Sec Filings
- 5/1/24 - Form 10-Q
- 4/24/24 - Form DEF
- 4/24/24 - Form ARS
- SRPT's page on the SEC website